Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28861472 | 0.95 | CYP1A2 (0.53) | CYP1A2ALDH1A1LTA4HFOLH1EPHX2 | |
| SCHEMBL16944361 | 0.90 | EPHX2 (0.54) | CYP1A2LTA4HEPHX2CASP2ADRA1A | |
| SCHEMBL13706974 | 0.90 | EPHX2 (0.54) | CYP1A2LTA4HEPHX2CASP2ADRA1A | |
| SCHEMBL12891255 | 0.90 | EPHX2 (0.54) | CYP1A2LTA4HEPHX2CASP2ADRA1A | |
| SCHEMBL13706976 | 0.90 | EPHX2 (0.54) | CYP1A2LTA4HEPHX2CASP2ADRA1A | |
| SCHEMBL12666256 | 0.90 | EPHX2 (0.54) | CYP1A2LTA4HEPHX2CASP2ADRA1A | |
| SCHEMBL12891252 | 0.90 | EPHX2 (0.54) | CYP1A2LTA4HEPHX2CASP2ADRA1A | |
| SCHEMBL13706958 | 0.89 | EPHX2 (0.52) | CYP1A2LTA4HEPHX2ADRA1APRMT1 | |
| SCHEMBL13706990 | 0.89 | EPHX2 (0.52) | CYP1A2LTA4HEPHX2ADRA1APRMT1 | |
| SCHEMBL13706991 | 0.89 | EPHX2 (0.52) | CYP1A2LTA4HEPHX2ADRA1APRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694089-B2 | Integrin targeting agents and in-vivo and in-vitro imaging methods using the same | VISEN MEDICAL, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20140170066-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | MERCK & CO., INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20110165075-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | MERCK SHARP & DOHME CORP. | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165075-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | ITGB3, ITGAV, ITGB1 | CYP1A2 4823/4885ALDH1A1 3601/4885LTA4H 766/4885 |
| US-20140170066-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | ITGB3, ITGAV, ITGB1 | CYP1A2 4823/4885ALDH1A1 3601/4885LTA4H 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.